Johnson & Johnson (NYSE:JNJ) announced it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 billion.
This acquisition provides an opportunity for the Janssen Pharmaceutical Companies of Johnson & Johnson to broaden its leadership in immune-mediated diseases and drive further growth through expansion into autoantibody-driven disease. The transaction will include full global rights to nipocalimab (M281), a clinically validated, potentially best-in-class anti-FcRn antibody. Nipocalimab gives Janssen the opportunity to reach significantly more patients by pursuing indications across many autoimmune diseases with substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Nipocalimab recently received a rare pediatric disease designation from the U.S. Food and Drug Administration. Momenta\u2019s expertise in FcRn mechanisms is especially important for nipocalimab as it supports and accelerates the development of a medicine designed to target a number of autoantibody-driven conditions across several of Janssen\u2019s established therapeutic areas. Janssen expects nipocalimab to contribute to its goals of achieving above-market growth over the mid and long term.
Autoimmune diseases driven partially or completely by autoantibodies represent a novel area where Janssen can significantly improve health outcomes for patients. In autoantibody-driven diseases, the body\u2019s antibodies attack or damage its own proteins, cells and tissues, often with devastating consequences. Autoantibody-driven diseases include Myasthenia Gravis, Hemolytic Diseases of the Fetus and Newborn, warm Autoimmune Hemolytic Anemia, and other serious dermatologic, rheumatic, neurologic, hematologic and renal diseases. An estimated 2.5 percent of the population, or approximately 195 million people worldwide, suffer from some form of autoantibody-driven disease, many of which are orphan and rare diseases.
With competitively differentiated, parallel development programs and full worldwide commercial rights for nipocalimab, Janssen will have the potential to introduce multiple \u00a0launches, many as first-in-class indications with potential for significant peak year sales, some of which could exceed $1 billion, supporting Janssen\u2019s goal of continuing to deliver above-market performance over the long term.
\u201cThis acquisition broadens Janssen\u2019s leadership in autoimmune diseases and provides us with a major catalyst for sustained growth. Autoantibody-driven diseases are often serious, and patients are underserved by current treatment options,” said Jennifer Taubert, Executive Vice President, Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. \u201cWe\u2019re excited by the opportunity to further advance patient care by combining Johnson & Johnson\u2019s world-class R&D, commercial and supply chain capabilities with Momenta\u2019s talented people, pipeline and deep expertise in this important area.\u201d<\/p>\n\n\n\n
In addition to Momenta\u2019s employees and lead asset nipocalimab, Janssen will acquire Momenta\u2019s pipeline of clinical and pre-clinical assets. The acquisition was driven by the significant opportunity seen in nipocalimab, along with the scientific capability Janssen is acquiring with the Momenta team. Janssen\u2019s plans for additional assets in the Momenta pipeline will be determined as more data become available and could offer further upside potential.<\/p>\n\n\n\n
\u201cNipocalimab, and the rest of Momenta\u2019s pipeline, built over many years by outstanding scientists who have turned important insights into actionable biology, expands and complements our portfolio by giving us clinical-stage and discovery-stage compounds in autoantibody biological pathways. Combining Momenta\u2019s discoveries with our 20-year heritage in immunology, global scope, and scientific and medical expertise, we see a real opportunity to create an entire \u2018pipeline in a pathway,\u2019 \u201d said Mathai Mammen, M.D., Ph.D., Global Head of Janssen Research & Development, Johnson & Johnson. \u201cWe are excited about the significant potential to expand on Momenta\u2019s excellent progress in rare diseases, and to increase our impact on patients both within and beyond our current focus areas.\u201d
Janssen plans to retain Momenta\u2019s presence in Cambridge, Massachusetts. This site will increase Johnson & Johnson\u2019s existing innovation footprint and capabilities in the greater Boston area given Momenta\u2019s talented scientists, suite of proprietary technologies, sophisticated laboratories and proximity to top talent in this innovation hub.<\/p>\n\n\n\n